Halozyme Therapeutics, Inc. (0J2O.L)
USD 61.37
(0.79%)
USD 61.37
(0.79%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 829.25 Million USD | 25.62% |
| 2022 | 660.11 Million USD | 48.91% |
| 2021 | 443.31 Million USD | 65.67% |
| 2020 | 267.59 Million USD | 36.53% |
| 2019 | 195.99 Million USD | 29.06% |
| 2018 | 151.86 Million USD | -52.04% |
| 2017 | 316.61 Million USD | 115.84% |
| 2016 | 146.69 Million USD | 8.61% |
| 2015 | 135.05 Million USD | 79.28% |
| 2014 | 75.33 Million USD | 37.47% |
| 2013 | 54.79 Million USD | 29.47% |
| 2012 | 42.32 Million USD | -24.54% |
| 2011 | 56.08 Million USD | 311.67% |
| 2010 | 13.62 Million USD | -0.35% |
| 2009 | 13.67 Million USD | 55.99% |
| 2008 | 8.76 Million USD | 130.66% |
| 2007 | 3.79 Million USD | 287.02% |
| 2006 | 981.74 Thousand USD | 671.76% |
| 2005 | 127.2 Thousand USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 25.7 Thousand USD | -70.71% |
| 2002 | 87.76 Thousand USD | 255.56% |
| 2001 | 24.68 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 231.35 Million USD | 18.11% |
| 2024 Q1 | 195.87 Million USD | -14.85% |
| 2024 Q3 | 290.08 Million USD | 25.39% |
| 2023 FY | 829.25 Million USD | 25.62% |
| 2023 Q1 | 162.14 Million USD | -10.66% |
| 2023 Q2 | 221.03 Million USD | 36.32% |
| 2023 Q4 | 230.03 Million USD | 6.48% |
| 2023 Q3 | 216.03 Million USD | -2.26% |
| 2022 Q4 | 181.49 Million USD | -13.15% |
| 2022 Q3 | 208.97 Million USD | 37.15% |
| 2022 Q1 | 117.27 Million USD | 14.98% |
| 2022 Q2 | 152.36 Million USD | 29.92% |
| 2022 FY | 660.11 Million USD | 48.91% |
| 2021 Q4 | 102 Million USD | -11.94% |
| 2021 Q3 | 115.83 Million USD | -15.11% |
| 2021 Q1 | 89.02 Million USD | -26.85% |
| 2021 Q2 | 136.45 Million USD | 53.28% |
| 2021 FY | 443.31 Million USD | 65.67% |
| 2020 Q3 | 65.31 Million USD | 18.28% |
| 2020 FY | 267.59 Million USD | 36.53% |
| 2020 Q4 | 121.7 Million USD | 86.33% |
| 2020 Q2 | 55.22 Million USD | 117.8% |
| 2020 Q1 | 25.35 Million USD | -52.76% |
| 2019 Q1 | 56.94 Million USD | -5.45% |
| 2019 FY | 195.99 Million USD | 29.06% |
| 2019 Q4 | 53.66 Million USD | 16.08% |
| 2019 Q3 | 46.23 Million USD | 18.09% |
| 2019 Q2 | 39.14 Million USD | -31.26% |
| 2018 Q4 | 60.23 Million USD | 135.69% |
| 2018 FY | 151.86 Million USD | -52.04% |
| 2018 Q1 | 30.87 Million USD | -83.71% |
| 2018 Q2 | 35.2 Million USD | 14.03% |
| 2018 Q3 | 25.55 Million USD | -27.4% |
| 2017 Q3 | 63.73 Million USD | 88.83% |
| 2017 Q4 | 189.56 Million USD | 197.44% |
| 2017 Q1 | 29.56 Million USD | -24.19% |
| 2017 Q2 | 33.75 Million USD | 14.14% |
| 2017 FY | 316.61 Million USD | 115.84% |
| 2016 Q3 | 31.85 Million USD | -4.45% |
| 2016 Q2 | 33.33 Million USD | -21.56% |
| 2016 Q1 | 42.49 Million USD | -18.63% |
| 2016 FY | 146.69 Million USD | 8.61% |
| 2016 Q4 | 39 Million USD | 22.45% |
| 2015 Q3 | 20.78 Million USD | -52.1% |
| 2015 Q1 | 18.66 Million USD | -38.55% |
| 2015 Q4 | 52.22 Million USD | 151.33% |
| 2015 FY | 135.05 Million USD | 79.28% |
| 2015 Q2 | 43.38 Million USD | 132.42% |
| 2014 Q3 | 14.6 Million USD | -20.55% |
| 2014 FY | 75.33 Million USD | 37.47% |
| 2014 Q4 | 30.37 Million USD | 107.98% |
| 2014 Q2 | 18.38 Million USD | 53.64% |
| 2014 Q1 | 11.96 Million USD | -4.26% |
| 2013 Q4 | 12.49 Million USD | -21.95% |
| 2013 Q1 | 11.83 Million USD | -45.7% |
| 2013 FY | 54.79 Million USD | 29.47% |
| 2013 Q2 | 14.45 Million USD | 22.14% |
| 2013 Q3 | 16.01 Million USD | 10.79% |
| 2012 Q3 | 5.33 Million USD | -31.23% |
| 2012 Q1 | 7.44 Million USD | 208.57% |
| 2012 Q2 | 7.75 Million USD | 4.26% |
| 2012 Q4 | 21.79 Million USD | 308.55% |
| 2012 FY | 42.32 Million USD | -24.54% |
| 2011 Q1 | 7.54 Million USD | 111.16% |
| 2011 FY | 56.08 Million USD | 311.67% |
| 2011 Q4 | 2.41 Million USD | -89.49% |
| 2011 Q3 | 22.94 Million USD | -1.06% |
| 2011 Q2 | 23.18 Million USD | 207.39% |
| 2010 Q3 | 3.39 Million USD | 5.7% |
| 2010 Q4 | 3.57 Million USD | 5.18% |
| 2010 FY | 13.62 Million USD | -0.35% |
| 2010 Q1 | 3.44 Million USD | -46.59% |
| 2010 Q2 | 3.21 Million USD | -6.64% |
| 2009 Q4 | 6.44 Million USD | 112.75% |
| 2009 Q2 | 1.42 Million USD | -48.56% |
| 2009 Q3 | 3.02 Million USD | 112.38% |
| 2009 FY | 13.67 Million USD | 55.99% |
| 2009 Q1 | 2.77 Million USD | -9.46% |
| 2008 Q4 | 3.06 Million USD | 24.37% |
| 2008 Q2 | 1.43 Million USD | -20.56% |
| 2008 Q1 | 1.8 Million USD | 34.95% |
| 2008 FY | 8.76 Million USD | 130.66% |
| 2008 Q3 | 2.46 Million USD | 71.68% |
| 2007 Q4 | 1.33 Million USD | 41.9% |
| 2007 Q3 | 942.88 Thousand USD | 33.08% |
| 2007 Q2 | 708.51 Thousand USD | -12.55% |
| 2007 Q1 | 810.21 Thousand USD | 90.05% |
| 2007 FY | 3.79 Million USD | 287.02% |
| 2006 Q2 | 119.66 Thousand USD | 63.29% |
| 2006 Q1 | 73.28 Thousand USD | 31.18% |
| 2006 FY | 981.74 Thousand USD | 671.76% |
| 2006 Q4 | 426.32 Thousand USD | 17.61% |
| 2006 Q3 | 362.47 Thousand USD | 202.92% |
| 2005 Q3 | 25.64 Thousand USD | -43.89% |
| 2005 Q4 | 55.86 Thousand USD | 117.84% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | 45.7 Thousand USD | 0.0% |
| 2005 FY | 127.2 Thousand USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q1 | - USD | -100.0% |
| 2004 FY | - USD | -100.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 Q4 | 2319.00 USD | -81.6% |
| 2003 Q3 | 12.6 Thousand USD | 58.37% |
| 2003 FY | 25.7 Thousand USD | -70.71% |
| 2003 Q1 | 2820.00 USD | -91.79% |
| 2003 Q2 | 7960.00 USD | 182.27% |
| 2002 FY | 87.76 Thousand USD | 255.56% |
| 2002 Q4 | 34.33 Thousand USD | 105.08% |
| 2002 Q1 | 28.86 Thousand USD | 0.0% |
| 2002 Q2 | 7827.00 USD | -72.89% |
| 2002 Q3 | 16.74 Thousand USD | 113.89% |
| 2001 FY | 24.68 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | -961.471% |
| Dynavax Technologies Corporation | 232.28 Million USD | -257.0% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -3854.85% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.438% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -36.498% |
| Perrigo Company plc | 4.65 Billion USD | 82.188% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -9572.845% |
| Illumina, Inc. | 4.5 Billion USD | 81.589% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 98.065% |
| Nektar Therapeutics | 90.12 Million USD | -820.145% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -69643.734% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 94.466% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -552.729% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 65.722% |
| Waters Corporation | 2.95 Billion USD | 71.951% |
| Biogen Inc. | 9.83 Billion USD | 91.569% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -370.546% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 202.08 Million USD | -310.349% |
| bluebird bio, Inc. | 29.49 Million USD | -2711.313% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -2553.695% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -612.821% |
| FibroGen, Inc. | 147.75 Million USD | -461.247% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 87.864% |
| Homology Medicines, Inc. | -6.65 Million USD | 12568.095% |
| Geron Corporation | 237 Thousand USD | -349795.781% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 54.643% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -107.648% |
| Myriad Genetics, Inc. | 678.4 Million USD | -22.237% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 93.678% |
| OPKO Health, Inc. | 863.49 Million USD | 3.966% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -2186.018% |
| Zoetis Inc. | 8.54 Billion USD | 90.294% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -23592.943% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 78.11% |
| Exelixis, Inc. | 1.83 Billion USD | 54.691% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 91.598% |
| uniQure N.V. | 15.84 Million USD | -5134.192% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -206.45% |
| Verastem, Inc. | - USD | -Infinity% |
| Imunon, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -5.282% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 33.304% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 56.057% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -71.91% |
| TG Therapeutics, Inc. | 233.66 Million USD | -254.894% |
| Blueprint Medicines Corporation | 249.38 Million USD | -232.526% |
| Insmed Incorporated | 305.2 Million USD | -171.701% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -2991.574% |
| Incyte Corporation | 3.69 Billion USD | 77.561% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 20.971% |